dipyridamole has been researched along with Inflammatory Bowel Diseases in 2 studies
Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.
Inflammatory Bowel Diseases: Chronic, non-specific inflammation of the GASTROINTESTINAL TRACT. Etiology may be genetic or environmental. This term includes CROHN DISEASE and ULCERATIVE COLITIS.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, H | 1 |
| Wang, Q | 1 |
| Huang, Y | 1 |
| Deng, J | 1 |
| Xie, X | 1 |
| Zhu, J | 1 |
| Yuan, Y | 1 |
| He, YM | 1 |
| Huang, YY | 1 |
| Luo, HB | 1 |
| He, X | 1 |
| Huang, B | 1 |
| Chen, Z | 1 |
| Geng, L | 1 |
| Wang, J | 1 |
| Liang, H | 1 |
| Cao, Y | 1 |
| Chen, H | 1 |
| Huang, W | 1 |
| Su, M | 1 |
| Wang, H | 2 |
| Xu, Y | 1 |
| Liu, Y | 1 |
| Lu, B | 1 |
| Xian, H | 1 |
| Li, H | 2 |
| Ren, L | 1 |
| Xie, J | 1 |
| Ye, L | 1 |
| Zhao, J | 1 |
| Chen, P | 1 |
| Zhang, L | 1 |
| Zhao, S | 1 |
| Zhang, T | 1 |
| Xu, B | 1 |
| Che, D | 1 |
| Si, W | 1 |
| Gu, X | 1 |
| Zeng, L | 1 |
| Wang, Y | 1 |
| Li, D | 1 |
| Zhan, Y | 1 |
| Delfouneso, D | 1 |
| Lew, AM | 1 |
| Cui, J | 1 |
| Tang, WH | 1 |
| Zhang, Y | 2 |
| Gong, S | 1 |
| Bai, F | 1 |
| Yang, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Controlled Trial to Evaluate the Outcomes With Aggrenox in Patients With SARS-CoV-2 Infection[NCT04410328] | Phase 3 | 99 participants (Actual) | Interventional | 2020-10-21 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 other studies available for dipyridamole and Inflammatory Bowel Diseases
| Article | Year |
|---|---|
Discovery of novel PDE4 inhibitors targeting the M-pocket from natural mangostanin with improved safety for the treatment of Inflammatory Bowel Diseases.
Topics: Aminopyridines; Animals; Benzamides; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; De | 2022 |
Mucosal Profiling of Pediatric-Onset Colitis and IBD Reveals Common Pathogenics and Therapeutic Pathways.
Topics: Antigens, CD; Apyrase; B-Lymphocytes; Cell Death; Cellular Microenvironment; Child; Cohort Studies; | 2019 |